Clinicopathological Features of Infiltrating Lobular Carcinomas Comparing with Infiltrating Ductal Carcinomas: a Case Control Study

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2010 Apr 29

PMID 20423478

Citations 23

Authors

Ju-Hyun Lee

Seho Park

Hyung Seok Park

Byeong-Woo Park

Affiliations

Soon will be listed here.

Abstract

Background: Infiltrating lobular carcinoma (ILC) is the second most common type of invasive breast cancers and it has been reported to have some unique biologic and epidemiologic characteristics.

Methods: Clinicopathological features of 95 patients with ILC, their relapse free survival (RFS) and overall survival (OS) were retrospectively investigated and compared with those of 3,621 patients with infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) between January 1984 and December 2005.

Results: ILC constitutes 2.3% of all invasive breast cancers. There were no difference between the ILC and the IDC-NOS groups regarding age at diagnosis, tumor size, nodal status, and treatment modalities except hormone therapy. The ILC group showed more estrogen receptor expression, less HER-2 expression and higher bilaterality. RFS and OS of the ILC patients were similar to those of the IDC. IDC-NOS metastasized more frequently to the lung and bone, whereas, ILC to the bone and ovary.

Conclusions: The incidence of ILC was relatively low in Korean breast cancer patients. Comparing to IDC-NOS ILC showed some different features such as higher estrogen receptor expression, less HER-2 expression, higher bilaterality and preferred metastatic sites of bone and ovary. Contralateral cancers and bone and ovary evaluation should be considered when monitoring ILC patients.

Citing Articles

Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.

Sung Y, Jeon T, Lee J, Oh J, An J, Kim A Breast Cancer. 2024; 32(1):186-196.

PMID: 39549221 DOI: 10.1007/s12282-024-01649-4.

Breast Cancer Subtype Prediction Model Employing Artificial Neural Network and F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography.

Hossain A, Chowdhury S J Med Phys. 2024; 49(2):181-188.

PMID: 39131430 PMC: 11309150. DOI: 10.4103/jmp.jmp_181_23.

Evaluation of an Artificial Intelligence System for Detection of Invasive Lobular Carcinoma on Digital Mammography.

Arce S, Vijay A, Yim E, Spiguel L, Hanna M Cureus. 2023; 15(5):e38770.

PMID: 37303390 PMC: 10249706. DOI: 10.7759/cureus.38770.

Breast biomarkers profile of invasive lobular carcinoma in a cohort of arab women shows no significant differences from carcinoma of no special type.

Al Nemer A Afr Health Sci. 2023; 22(4):10-15.

PMID: 37092099 PMC: 10117450. DOI: 10.4314/ahs.v22i4.3.

Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.

Danzinger S, Pockl K, Kronawetter G, Pfeifer C, Behrendt S, Gscheidlinger P Wien Klin Wochenschr. 2023; 135(17-18):463-471.

PMID: 37010596 PMC: 10497662. DOI: 10.1007/s00508-023-02162-y.

References

Dixon J, Anderson T, Page D, Lee D, Duffy S, Stewart H . Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg. 1983; 70(9):513-6. DOI: 10.1002/bjs.1800700902. View

Du Toit R, Locker A, Ellis I, Elston C, Nicholson R, Blamey R . Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. Br J Cancer. 1989; 60(4):605-9. PMC: 2247102. DOI: 10.1038/bjc.1989.323. View

Kim M, Ro J, Ahn S, Kim H, Kim S, Gong G . Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9):1217-26. DOI: 10.1016/j.humpath.2006.04.015. View

Arpino G, Bardou V, Clark G, Elledge R . Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6(3):R149-56. PMC: 400666. DOI: 10.1186/bcr767. View

Winchester D, Chang H, Graves T, Menck H, Bland K, WINCHESTER D . A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg. 1998; 186(4):416-22. DOI: 10.1016/s1072-7515(98)00051-9. View

Poen J, Tran L, Juillard G, Selch M, Giuliano A, Silverstein M . Conservation therapy for invasive lobular carcinoma of the breast. Cancer. 1992; 69(11):2789-95. DOI: 10.1002/1097-0142(19920601)69:11<2789::aid-cncr2820691126>3.0.co;2-j. View

Yaziji H, Goldstein L, Barry T, Werling R, Hwang H, Ellis G . HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291(16):1972-7. DOI: 10.1001/jama.291.16.1972. View

Harake M, Maxwell A, Sukumar S . Primary and metastatic lobular carcinoma of the breast. Clin Radiol. 2001; 56(8):621-30. DOI: 10.1053/crad.2001.0766. View

Soslow R, Carlson D, Horenstein M, Osborne M . A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat. 2000; 61(2):161-70. DOI: 10.1023/a:1006479113769. View

10.

Lehr H, Folpe A, Yaziji H, Kommoss F, Gown A . Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol. 2000; 114(2):190-6. DOI: 10.1309/CPUX-KWEH-7B26-YE19. View

11.

Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T . Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996; 77(1):113-20. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8. View

12.

Ko S . Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol. 2008; 98(5):318-23. DOI: 10.1002/jso.21110. View

13.

Mate T, Carter D, Fischer D, Hartman P, MCKHANN C, Merino M . A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer. 1986; 58(9):1995-2002. DOI: 10.1002/1097-0142(19861101)58:9<1995::aid-cncr2820580907>3.0.co;2-1. View

14.

MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F . Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol. 1997; 10(8):769-76. View

15.

Singletary S, Patel-Parekh L, Bland K . Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg. 2005; 242(2):281-9. PMC: 1357735. DOI: 10.1097/01.sla.0000171306.74366.22. View

16.

Li C, Anderson B, Porter P, Holt S, Daling J, Moe R . Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000; 88(11):2561-9. View

17.

Lamovec J, Zidar A . Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991; 115(5):507-10. View

18.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S, Broglio K, Theriault R . Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2004; 23(1):41-8. DOI: 10.1200/JCO.2005.03.111. View

19.

Egervari K, Szollosi Z, Nemes Z . Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol. 2008; 29(1):18-27. DOI: 10.1159/000132567. View

20.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View